Podcasts about pseudoprogression

Dr. Ankush Bhatia interviews Dr.François Ducray about his and his team's recent manuscript entitled:"Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study", published online in Neuro-Oncology in March 2023.  

As part of its OncView™ video series, CancerNetwork® spoke with John Kirkwood, MD, PhD, director of the melanoma center at the University of Pittsburgh Medical Center Hillman Cancer Center, about using immunotherapy for treating melanoma and how to monitor responses in patients properly. In the video series, Kirkwood discussed the following: ·      Treatment Options for Melanoma ·      Considerations for Immunotherapy Use When Treating Melanoma ·      Monitoring Responses to Melanoma Therapy ·      Pseudoprogression in Melanoma Therapy ·      ctDNA for Melanoma Treatment Monitoring ·      Using ctDNA to Monitor Patients With Melanoma ·      Taking Drug Holidays Amidst Melanoma Therapy ·      Duration of Treatment for Melanoma To watch more videos in CancerNetwork®'s OncView™ series, visit cancernetwork.com/oncview. Don't forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Podcast Contents 00:00-02:25- Introduction by David A. Bluemke, MD, PhD, Editor of Radiology. 02:26- 09:13– Continuous Learning AI in Radiology: Implementation Principles and Early Applications. Pianykh et al. Radiology 2020; 297:6–14. 05:11- 07:02– Cardiovascular CT and MRI in 2019: Review of Key Articles. Dodd and Leipsic. Radiology 2020; 297:17–30. 07:03- 09:13- Range of Radiologist Performance in a Population-based Screening Cohort of 1 Million Digital Mammography Examinations. Salim et al. Radiology 2020; 297:33–39. 09:14- 12:11– Myocardial Fibrosis and Inflammation in Liver Cirrhosis: MRI Study of the Liver-Heart Axis. Isaak and Praktiknjo et al. Radiology 2020; 297:51–61.  12:12-16:24– Automated Abdominal CT Imaging Biomarkers for Opportunistic Prediction of Future Major Osteoporotic Fractures in Asymptomatic Adults. Pickhardt et al. Radiology 2020; 297:64–72. 16:25-18:25- Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Park et al. Radiology 2020; 297:87–96. 18:26-19:05- Conclusion by David A. Bluemke, MD, PhD, Editor of Radiology RSNA2020 Virtual Meeting https://www.rsna.org/annual-meeting

On this episode of CANCER BUZZ, learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency departments providers need to know about immune-related adverse events in patients treated with checkpoint inhibitors.Guest:Sarah Dubbs, MD, Assistant Professor in Emergency Medicine; Assistant Director of the Emergency Medicine Residency Program, University of Maryland School of MedicineRelevant Content:IO Wallet Card, by the ACCC Immuno-Oncology Institute“IO Patients in the Emergency Department,” by Junaid Razzak, MBBS, MD, PhD“Communication: Key to Addressing Toxicity and Recurrence Risks,” by Mark B. Faries, MD“Immunotherapy Complications in the Emergency Department,” by Adarsh Srivastava, MD, American Academy of Emergency Medicine“Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians,” by Adam T. Hryniewicki et al.“Pseudoprogression in Patients Treated with Immunotherapy,” by Ryan M. Weight, DO, MSThe views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.

Lung Cancer Update – Part 2: Our interview with Dr Chaft highlights the following topics as well as cases from her practice: Case: A 54-year-old woman and never smoker presenting with arthralgias, digital clubbing and leg edema is diagnosed with Stage IIIA NSCLC and an EGFR exon 19 deletion: 0m0s Evaluation of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for NSCLC: 3m2s Predictors of clinical benefit from neoadjuvant therapy with immune checkpoint inhibitors: 6m41s Selection of patients for neoadjuvant therapy with anti-PD-1/PD-L1 antibodies: 7m52s Choice of adjuvant therapy for patients with NSCLC and an EGFR tumor mutation: 12m10s Risks and benefits with osimertinib in the adjuvant setting: 14m38s Status of the Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST) for patients with early-stage lung cancer: 17m31s Results of the Phase III SELECT trial of adjuvant erlotinib for resected NSCLC with an EGFR tumor mutation: 19m5s Case: A 59-year-old man and former smoker with unresectable, Stage III NSCLC receives durvalumab as consolidation therapy after chemoradiation therapy: 22m58s Management of superior vena cava syndrome in patients with lung cancer: 25m23s Activity and tolerability of durvalumab as consolidation therapy: 27m50s Perspective on the results of the PACIFIC trial of durvalumab after chemoradiation therapy for Stage III NSCLC: 29m15s Recognition and management of pneumonitis associated with durvalumab/radiation therapy: 30m53s Impact of baseline steroids on the efficacy of PD-1/PD-L1 blockade in patients with NSCLC: 35m7s Effects of tumor mutations and PD-L1 expression on response to checkpoint inhibitors: 36m54s Case: A 68-year-old woman and smoker experiences recurrent colitis after receiving nivolumab for metastatic NSCLC: 40m11s Incidence and mitigation of diarrhea and colitis associated with checkpoint inhibitors: 42m45s Management of metastatic nonsquamous NSCLC in the first-line setting: 46m0s Perspective on the results of the Phase III IMpower150 study: 49m47s Selection of first-line therapy for patients with metastatic squamous NSCLC: 53m3s Risks and benefits of nivolumab with ipilimumab for metastatic NSCLC: 54m44s Therapeutic approach for patients with metastatic small cell lung cancer: 58m18s Duration of therapy with immune checkpoint inhibitors: 1h0m23s Pseudoprogression and hyperprogression associated with immune checkpoint inhibitors: 1h2m18s Case: A 64-year-old woman with metastatic NSCLC and an ALK rearrangement receives alectinib after developing intolerance to crizotinib: 1h4m40s Efficacy and side effects of the ALK inhibitors alectinib, brigatinib and lorlatinib: 1h7m21s Select publications

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".